Investigational — not approved anywhere

Ulotaront

Open Ulotaront in the interactive console ↗

Pronunciation: yoo-LOE-ta-ront

Ulotaront ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Ulotaront ballicule

Ulotaront mascot mnemonic cartoon — Visual mnemonic: Ulotaront mascot
**“YOLO Toronto!”**

What it isUlotaront is an investigational trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity that lacks direct dopamine D2 receptor blockade.

Why this oneIt was developed as a non-D2 antipsychotic for schizophrenia intended to avoid extrapyramidal and metabolic adverse effects.

What limits itIt failed to separate from placebo in the Phase 3 DIAMOND 1 and DIAMOND 2 trials and is not FDA approved.

Ulotaront molecular structure (skeletal formula) — Molecular structure: Ulotaront

NO BOXED WARNINGS

Principal riskNo FDA boxed warning (investigational).

Classes and tags

Trace amine-associated receptor 1 (TAAR1) agonists

Clinical profile

Therapeutic safety burden2 / 4

Overdose danger2 / 4

Weight-gain liability0 / 4

Sedation liability1 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Open Ulotaront in the interactive console ↗